Vasomotor symptoms (Hot flashes/Night sweats)– Epidemiology Forecast—2030

‘Vasomotor symptoms (Hot flashes/Night sweats)– Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Vasomotor symptoms including Hot flashes or night sweats, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom) and Japan.
Vasomotor symptoms (Hot flashes/Night sweats) Disease Understanding
Vasomotor symptoms are one of the major symptoms of menopause that principally include hot flashes (HF) and night sweats (NS) and occurs in the majority of women across the globe. A woman with VMS experiences abundant heat accompanied by sweating and flushing, especially around the head, neck, chest, and upper back region. These are the menopausal symptoms for which women seek treatment during menopause most often. VMS results from temperature dysfunction that occurs due to changes in gonadal hormones. Normally, core body temperature (CBT) remains within a specific range, oscillating with daily circadian rhythms.
Menopause is characterized by physiologic and psychosocial changes in a woman's life. VMS, and the sleep and mood disturbances that often result from these, can have a significant negative impact on the overall quality of life (QOL) for a substantial number of women. The impact of VMS has gained in importance as the lifespan of women has increased throughout the world since women can expect to spend a significant portion of their lives after menopause. Maintenance of functional ability and a good QOL is of utmost importance. Given the prevalence and duration of VMS among midlife women, it is critical to understand the underlying biology of this symptom, the extent to which VMS may impair QOL, and whether VMS may serve as a marker for other important health conditions. VMS experienced in up to 80% of menopausal women, prevalence depends on region. The vasomotor symptoms may range in severity from discomfort to debilitation. More than half of the women with VMS experience “moderate to severe” symptoms.
Vasomotor symptoms (Hot flashes/Night sweats) Epidemiology
The Vasomotor symptoms epidemiology division provide insights about the historical and current patient pool of Hot flashes/Night sweats and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Report report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The total diagnosed prevalent cases of vasomotor symptoms (Hot flashes/Night sweats) patients were found to be more in postmenopausal women aged 40—65 years in 7MM during the study period, i.e. 2017-2030.
The disease epidemiology covered in the report provides historical as well as forecasted vasomotor symptoms epidemiology segmented as the prevalence of Vasomotor symptoms, Prevalent Cases of Hot Flashes associated with Post Menopause, Severity-specific cases of Hot flashes (Mild, Moderate and Severe) in post-menopause and Diagnosed and Treatable Cases of Vasomotor symptoms.
The report includes the prevalent scenario of Vasomotor symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
Country Wise- Vasomotor symptoms (Hot flashes/Night sweats) Epidemiology
The epidemiology segment also provides the Vasomotor symptoms (Hot flashes/Night sweats) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The total prevalent population of Vasomotor Symptoms Associated with post-menopause in 7MM countries was found to be 41,096,968 in 2017.
• As per the estimates, United States has the highest prevalent population of Hot Flashes associated with Post Menopause.
• Among the European countries, Germany had the highest prevalent population of Hot Flashes and Spain had the lowest prevalent population in 2017.
Scope of the Report
• The Vasomotor symptoms (Hot flashes/Night sweats) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Vasomotor symptoms (Hot flashes/Night sweats) Epidemiology Report and Model provide an overview of the risk factors and global trends of Vasomotor symptoms (Hot flashes/Night sweats) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight about the historical and forecasted patient pool of Vasomotor symptoms (Hot flashes/Night sweats) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Vasomotor symptoms
• The report provides the segmentation of the Vasomotor symptoms (Hot flashes/Night sweats) epidemiology by -specific Prevalent Cases of Vasomotor symptoms (Hot flashes/Night sweats) in 7MM
• The report provides the segmentation of the Vasomotor symptoms (Hot flashes/Night sweats) epidemiology by Gender-specific Cases of Vasomotor symptoms (Hot flashes/Night sweats) in 7MM
Report Highlights
• 11-Year Forecast of Vasomotor symptoms (Hot flashes/Night sweats) epidemiology
• 7MM Coverage
• Total Prevalent Cases of Vasomotor symptoms (Hot flashes/Night sweats) in post menopause
• Prevalent Cases according to segmentation: Severity-specific Prevalence of hot flashes
• Diagnosed cases of Vasomotor symptoms
KOL- Views
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Vasomotor symptoms?
• What are the key findings pertaining to the Vasomotor symptoms (Hot flashes/Night sweats) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
• What would be the total number of patients of Vasomotor symptoms (Hot flashes/Night sweats) across the 7MM during the forecast period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
• What is the disease risk, burden and unmet needs of the Vasomotor symptoms?
• What are the currently available treatments of Vasomotor symptoms?
Reasons to buy
The Vasomotor symptoms (Hot flashes/Night sweats) Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Vasomotor symptoms (Hot flashes/Night sweats) market
• Quantify patient populations in the global Vasomotor symptoms (Hot flashes/Night sweats) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Vasomotor symptoms (Hot flashes/Night sweats) therapeutics in each of the markets covered
• Understand the magnitude of Vasomotor symptoms (Hot flashes/Night sweats) population by its severity
• The Vasomotor symptoms (Hot flashes/Night sweats) epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The Vasomotor symptoms (Hot flashes/Night sweats) Epidemiology Model developed by Report is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030
With the aging of the worldwide population in the coming decades, it is estimated that 1.2 billion women worldwide will be menopausal or postmenopausal by the year 2030. Among them, Vasomotor symptoms, Hot flashes are extremely common affecting approximately 85% of menopausal women. Nearly 55% of women experience Hot flashes as they enter the transition phase toward menopause. In the post-menopause, Hot flashes becoming most troublesome with increasing severity.

The International Menopause Society (IMS) Council of Affiliated Menopause Societies (CAMS) have collaborated in studies to compare the prevalence of HFs in different climates, continents and at different altitudes.
Severity-specific prevalence of Hot Flashes and Sweat nights: A large number of women reported moderate to severe vasomotor symptoms. Perimenopausal women showed more severe symptoms as compared to women in the post-menopause stage. The frequency and severity of Night Sweats were lower than that of Hot Flashes, yet it may greatly impact women's health through the loss of sleep. Additionally, one’s lifestyle and environmental factors have been reported to either worsen the symptoms or make them better. Hot flashes were reported to be worse in the evening for approximately one-third of postmenopausal women.
The prevalence of hot flashes in Japan is lower than in western countries. The remarkably lower prevalence of menopausal symptoms such as Hot Flashes among Japanese women compared with their counterparts in the western countries challenged the conventional view of menopause as a biologically uniform experience.